Clinical Trials
51 trialsA Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study
Genentech, Inc.
CLEAR-04
Fudan University
CLEAR-02
Fudan University
FUDOSE
UNICANCER
INAVO-CRC
Hoffmann-La Roche
Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation
Cardiff Oncology
LIVERPEARL
Grupo Espanol Multidisciplinario del Cancer Digestivo
ONTOP
Shanghai Pudong Hospital
DeFianCe
Leap Therapeutics, Inc.
SAMCO
Federation Francophone de Cancerologie Digestive
OPTIPRIME
Federation Francophone de Cancerologie Digestive
Hypo-OPRA
McGill University Health Centre/Research Institute of the McGill University Health Centre
COSENSE-1
St. Olavs Hospital
EGIA-003
Alethia Biotherapeutics
CLavSyn
Centre Hospitalier Universitaire de Besancon
SI-B001 as a Single Agent or in Combination With Chemotherapy in the Treatment of Digestive System Malignancies
Sichuan Baili Pharmaceutical Co., Ltd.
Cadonilimab in Combination With Bevacizumab and FOLFOX Regimen for the First-Line Treatment of Advanced Unresectable MSS-Type, RAS-Mutated Metastatic Colorectal Cancer
Fudan University
Reolysin in Combination With FOLFOX6 and Bevacizumab or FOLFOX6 and Bevacizumab Alone in Metastatic Colorectal Cancer
Canadian Cancer Trials Group
INTERACT-II
Catharina Ziekenhuis Eindhoven
FOLFOX/FOLFIRI Containing Levofolinic Acid (Zuoyu ®) in the Treatment of Unresectable or Metastatic Colorectal Cancer
China Medical University, China
Study of Vitamin D in Untreated Metastatic Colorectal Cancer
Dana-Farber Cancer Institute
REPAN
King Abdullah Medical City
Comparison of Combination Chemotherapy Regimens in Treating Patients With Metastatic Colorectal Cancer
UNICANCER
Combination Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver
UNICANCER
1st Line Chemotherapy Alone or With Bevacizumab in Treating Older Patients With Metastatic Colorectal Cancer
Federation Francophone de Cancerologie Digestive
Novel Oncology Therapies in Combination With Adjuvant Chemo in High-risk MSS-CRC
MedImmune LLC
Complete Neoadjuvant Treatment for REctal Cancer (CONTRE)
Brown University
Combination Chemotherapy and Intensity-Modulated Radiation Therapy in Treating Patients Undergoing Surgery for Locally Advanced Rectal Cancer
Radiation Therapy Oncology Group
A Study to Determine the Activity of Robatumumab (SCH 717454, MK-7454) in Participants With Relapsed or Recurrent Colorectal Cancer (P04721, MK-7454-003)
Merck Sharp & Dohme LLC
PULSE
Grupo Espanol Multidisciplinario del Cancer Digestivo
Apatinib Treatment as the Neoadjuvant Therapy in Advanced Colorectal Cancer
Sichuan Provincial People's Hospital
NEOLAR
Zealand University Hospital
FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment in Patients With Metastatic Colorectal Cancer
Genentech, Inc.
BOS2
European Organisation for Research and Treatment of Cancer - EORTC
Adoptive Cell Therapy Plus Chemotherapy and Radiation After Surgery in Treating Patients With Colorectal Cancer
Shenzhen Hornetcorn Bio-technology Company, LTD
Study to Evaluate the Safety, Tolerability and Efficacy of FOLFOX + CT-011 Versus FOLFOX Alone
Medivation, Inc.
FOLFOXIRI Compared to FOLFOX in First Line Treatment of Metastatic Colorectal Cancer
Sun Yat-sen University
Fluorouracil and Leucovorin With or Without Oxaliplatin in Treating Patients With Recurrent Metastatic Colorectal Cancer
National Cancer Institute (NCI)
Isolated Hepatic Perfusion With Melphalan Followed by Combination Chemotherapy in Treating Patients With Unresectable Liver Metastases From Colorectal Cancer
National Cancer Institute (NCI)
Gefitinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Colorectal Cancer
National Cancer Institute (NCI)
A Study Combining FOLFOX or FOLFIRI With AG-013736 or Bevacizumab (Avastin) in Patients With Metastatic Colorectal Cancer After Failure Of One First Line Regimen
Pfizer
Safety and Efficacy Study of Combination Therapy With Cetuximab and FOLFOX4 in Patients With Colorectal Cancer
Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer Previously Treated With Irinotecan
National Cancer Institute (NCI)
Chemotherapy and Bevacizumab With or Without Radiofrequency Ablation in Treating Unresectable Liver Metastases in Patients With Colorectal Cancer
European Organisation for Research and Treatment of Cancer - EORTC
MT201-204
Amgen Research (Munich) GmbH
Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer
NYU Langone Health
FOLFOX4 Combined With Endostar in Patients With Advanced Colorectal Cancer
Simcere Pharmaceutical Co., Ltd
Biomarkers in Predicting Neurotoxicity in Patients With Colorectal Cancer Receiving Oxaliplatin
National Cancer Institute (NCI)
Cetuximab in Neoadjuvant Treatment of Non-Resectable Colorectal Liver Metastases (CELIM)
Technische Universität Dresden
Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer
National Cancer Institute (NCI)